A Study of MB-CART19.1 Cellular Therapy for People With Central Nervous System Lymphoma (CNSL)

Recruiting now · Phase 1

Conditions studied: Primary Central Nervous System (CNS) Lymphoma, Secondary Central Nervous System Lymphoma

In brief

This study will test whether MB-CART19.1 is a safe and effective treatment for central nervous system lymphoma (CNSL). This study will test different doses of MB-CART19.1 to find the highest dose that causes few or mild side effects in participants.

Key facts

Study ID: NCT07137494
Run by: Memorial Sloan Kettering Cancer Center
People needed: 12
Starts: 2025-08-14
Expected to finish: 2028-08-01
Last updated by the study team: 2026-06-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Men and women who are at least 18 years of age on the day of consenting to the study.
Histologically documented primary or secondary central nervous system lymphoma of DLBCL subtype
Relapsed/refractory primary or secondary CNSL patients. All relapsed//refractory patients need to have received at least one prior CNS-directed methotrexate-based therapy. There is no restriction on the number of recurrences.
For relapsed patients, parenchymal lesions must have unequivocal evidence of disease progression on imaging (MRI of the brain or head CT) within 21 days of study consent.
For refractory patients, there must be residual disease after their last line of therapy.
For patients with leptomeningeal disease only, CSF cytology and/or flow cytometry must document CSF findings consistent with CSF involvement by lymphoma and/or imaging findings consistent with CSF disease within 21 days of study registration (at the discretion of the investigator).
Creatinine Clearance ≥ 40 ml/min/m2, direct bilirubin ≤2.0 mg/100 ml, AST and ALT ≤3.0x upper limit of normal (ULN)
Adequate pulmonary function as assessed by ≥90% oxygen saturation on room air by pulse oximetry.
Must be able to tolerate both MRI and CT scans
Must be able to tolerate lumbar puncture and/or Ommaya taps
Must have been either off corticosteroids, or on a stable or decreasing dose of dexamethasone equivalent ≤ 2 mg daily for 7 days before apheresis and 72 hours prior to CAR T cell infusion o Use of corticosteroids to treat CAR T cell toxicities per MSKCC guidelines is permitted

You may not qualify if…

ECOG performance status >2
o Patients with ECOG status of 2 will be enrolled at the discretion of the PI
Active systemic lymphoma (i.e. involvement outside of the CNS)
If the most recent CSF or brain tissue sample demonstrates absence of CD19 expression
Size of any single CNS lymphoma lesion exceeds 3 cm in maximal diameter in eloquent brain structures.
Prior treatment of systemic lymphoma with CD19-targeted CAR T cells
Pregnant or lactating patients. Patients of childbearing age should use effective contraception while on this study and continue for 1 year after all treatment is finished.
Impaired cardiac function (LVEF <40%) as assessed by most recent ECHO in the last 1 year.
Patients with autoimmune disease requiring systemic T cell-suppressive therapy.
Patients with following cardiac conditions will be excluded:
New York Heart Association (NYHA) stage III or IV congestive heart failure
Myocardial infarction ≤6 months prior to enrollment
History of clinically significant ventricular arrhythmia or unexplained syncope, not believed to be vasovagal in nature or due to dehydration ≤6 months prior to enrollment
Patients with ocular lymphoma in the absence of other CNS involvement
Patient has received chemotherapy, monoclonal antibodies or targeted anticancer therapy ≤ 4 weeks or 5 half-lives, whichever is shorter, or 6 weeks for nitrosourea or mitomycin-C, or 3 months since allogeneic hematopoietic stem cell transplantation, prior to starting the study drug, or the patient has not recovered from the side effects of such therapy.
Patients with HIV
Patients with active hepatitis B or hepatitis C infection (as manifested by either detectable hepatitis B virus DNA by PCR, hepatitis virus C RNA by PCR, or positivity for hepatitis B surface or core antigen)
Patients with uncontrolled systemic fungal, bacterial, viral or other infection at time of leukapheresis or at time of CAR T cell infusion
Patients with any concurrent active malignancies as defined by malignancies requiring any therapy other than expectant observation or hormonal therapy, with the exception of squamous and basal cell carcinoma of skin
Patients exposed to immune checkpoint inhibitor within 8 weeks
Use of herbal supplements are not allowed on study
Any other issue which, in the opinion of the treating physician or PI, would make the patient ineligible for the study.

Where it is running

Memorial Sloan Kettering at Basking Ridge (All Protocol Activities) — Basking Ridge, New Jersey, United States (enrolling)
Memorial Sloan Kettering at Monmouth (Limited Protocol Activities) — Middletown, New Jersey, United States (enrolling)
Memorial Sloan Kettering at Bergen (Limited Protocol Activities) — Montvale, New Jersey, United States (enrolling)
Memorial Sloan Kettering at Suffolk-Commack (Limited Protocol Activities) — Commack, New York, United States (enrolling)
Memorial Sloan Kettering at Westchester (Limited Protocol Activities) — Harrison, New York, United States (enrolling)
Memorial Sloan Kettering Cancer Center (All Protocol Activities) — New York, New York, United States (enrolling)
Memorial Sloan Kettering at Nassau (Limited Protocol Activities) — Uniondale, New York, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.